Copyright Reports & Markets. All rights reserved.

Global Immune Checkpoint Inhibitors Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Immune Checkpoint Inhibitors Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Product
      • 1.4.2 PD-1/PD-L1
      • 1.4.3 CTLA-4
    • 1.5 Market by End User
      • 1.5.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by End User
      • 1.5.2 Lung Cancer
      • 1.5.3 Colorectal Cancer
      • 1.5.4 Breast Cancer
      • 1.5.5 Prostate Cancer
      • 1.5.6 Melanoma
      • 1.5.7 Blood Cancer
      • 1.5.8 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Immune Checkpoint Inhibitors Market Size
      • 2.1.1 Global Immune Checkpoint Inhibitors Revenue 2014-2025
      • 2.1.2 Global Immune Checkpoint Inhibitors Sales 2014-2025
    • 2.2 Immune Checkpoint Inhibitors Growth Rate by Regions
      • 2.2.1 Global Immune Checkpoint Inhibitors Sales by Regions
      • 2.2.2 Global Immune Checkpoint Inhibitors Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Immune Checkpoint Inhibitors Sales by Manufacturers
      • 3.1.1 Immune Checkpoint Inhibitors Sales by Manufacturers
      • 3.1.2 Immune Checkpoint Inhibitors Sales Market Share by Manufacturers
      • 3.1.3 Global Immune Checkpoint Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Immune Checkpoint Inhibitors Revenue by Manufacturers
      • 3.2.1 Immune Checkpoint Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2014-2019)
    • 3.3 Immune Checkpoint Inhibitors Price by Manufacturers
    • 3.4 Immune Checkpoint Inhibitors Manufacturing Base Distribution, Product Types
      • 3.4.1 Immune Checkpoint Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Immune Checkpoint Inhibitors Product Type
      • 3.4.3 Date of International Manufacturers Enter into Immune Checkpoint Inhibitors Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Immune Checkpoint Inhibitors Sales by Product
    • 4.2 Global Immune Checkpoint Inhibitors Revenue by Product
    • 4.3 Immune Checkpoint Inhibitors Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Immune Checkpoint Inhibitors Breakdown Data by End User

    6 North America

    • 6.1 North America Immune Checkpoint Inhibitors by Countries
      • 6.1.1 North America Immune Checkpoint Inhibitors Sales by Countries
      • 6.1.2 North America Immune Checkpoint Inhibitors Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Immune Checkpoint Inhibitors by Product
    • 6.3 North America Immune Checkpoint Inhibitors by End User

    7 Europe

    • 7.1 Europe Immune Checkpoint Inhibitors by Countries
      • 7.1.1 Europe Immune Checkpoint Inhibitors Sales by Countries
      • 7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Immune Checkpoint Inhibitors by Product
    • 7.3 Europe Immune Checkpoint Inhibitors by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Immune Checkpoint Inhibitors by Countries
      • 8.1.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Countries
      • 8.1.2 Asia Pacific Immune Checkpoint Inhibitors Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Immune Checkpoint Inhibitors by Product
    • 8.3 Asia Pacific Immune Checkpoint Inhibitors by End User

    9 Central & South America

    • 9.1 Central & South America Immune Checkpoint Inhibitors by Countries
      • 9.1.1 Central & South America Immune Checkpoint Inhibitors Sales by Countries
      • 9.1.2 Central & South America Immune Checkpoint Inhibitors Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Immune Checkpoint Inhibitors by Product
    • 9.3 Central & South America Immune Checkpoint Inhibitors by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Immune Checkpoint Inhibitors by Countries
      • 10.1.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Countries
      • 10.1.2 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Immune Checkpoint Inhibitors by Product
    • 10.3 Middle East and Africa Immune Checkpoint Inhibitors by End User

    11 Company Profiles

    • 11.1 Bristol Myer Squibb
      • 11.1.1 Bristol Myer Squibb Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products Offered
      • 11.1.5 Bristol Myer Squibb Recent Development
    • 11.2 AstraZeneca
      • 11.2.1 AstraZeneca Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 AstraZeneca Immune Checkpoint Inhibitors Products Offered
      • 11.2.5 AstraZeneca Recent Development
    • 11.3 Merck & Co.
      • 11.3.1 Merck & Co. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck & Co. Immune Checkpoint Inhibitors Products Offered
      • 11.3.5 Merck & Co. Recent Development
    • 11.4 Roche / Genentech
      • 11.4.1 Roche / Genentech Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Roche / Genentech Immune Checkpoint Inhibitors Products Offered
      • 11.4.5 Roche / Genentech Recent Development
    • 11.5 Incyte Corporation
      • 11.5.1 Incyte Corporation Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Incyte Corporation Immune Checkpoint Inhibitors Products Offered
      • 11.5.5 Incyte Corporation Recent Development
    • 11.6 NewLink Genetics
      • 11.6.1 NewLink Genetics Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 NewLink Genetics Immune Checkpoint Inhibitors Products Offered
      • 11.6.5 NewLink Genetics Recent Development
    • 11.7 ArGEN-X
      • 11.7.1 ArGEN-X Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 ArGEN-X Immune Checkpoint Inhibitors Products Offered
      • 11.7.5 ArGEN-X Recent Development
    • 11.8 Seattle Genetics
      • 11.8.1 Seattle Genetics Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Seattle Genetics Immune Checkpoint Inhibitors Products Offered
      • 11.8.5 Seattle Genetics Recent Development
    • 11.9 Pfizer
      • 11.9.1 Pfizer Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Pfizer Immune Checkpoint Inhibitors Products Offered
      • 11.9.5 Pfizer Recent Development
    • 11.10 MacroGenics
      • 11.10.1 MacroGenics Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 MacroGenics Immune Checkpoint Inhibitors Products Offered
      • 11.10.5 MacroGenics Recent Development
    • 11.11 Celldex Therapeutics
    • 11.12 CureTech
    • 11.13 Immutep
    • 11.14 Innate Pharma
    • 11.15 Sorrento Therapeutics
    • 11.16 GlaxoSmithKline
    • 11.17 GITR, Inc

    12 Future Forecast

    • 12.1 Immune Checkpoint Inhibitors Market Forecast by Regions
      • 12.1.1 Global Immune Checkpoint Inhibitors Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.2 Immune Checkpoint Inhibitors Market Forecast by Product
      • 12.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Product 2019-2025
      • 12.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Product 2019-2025
    • 12.3 Immune Checkpoint Inhibitors Market Forecast by End User
    • 12.4 North America Immune Checkpoint Inhibitors Forecast
    • 12.5 Europe Immune Checkpoint Inhibitors Forecast
    • 12.6 Asia Pacific Immune Checkpoint Inhibitors Forecast
    • 12.7 Central & South America Immune Checkpoint Inhibitors Forecast
    • 12.8 Middle East and Africa Immune Checkpoint Inhibitors Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Immune Checkpoint Inhibitors Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
      The global Immune Checkpoint Inhibitors market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Immune Checkpoint Inhibitors market based on company, product type, end user and key regions.

      This report studies the global market size of Immune Checkpoint Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Immune Checkpoint Inhibitors in these regions.
      This research report categorizes the global Immune Checkpoint Inhibitors market by top players/brands, region, type and end user. This report also studies the global Immune Checkpoint Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Bristol Myer Squibb
      AstraZeneca
      Merck & Co.
      Roche / Genentech
      Incyte Corporation
      NewLink Genetics
      ArGEN-X
      Seattle Genetics
      Pfizer
      MacroGenics
      Celldex Therapeutics
      CureTech
      Immutep
      Innate Pharma
      Sorrento Therapeutics
      GlaxoSmithKline
      GITR, Inc

      Market size by Product
      PD-1/PD-L1
      CTLA-4
      Market size by End User
      Lung Cancer
      Colorectal Cancer
      Breast Cancer
      Prostate Cancer
      Melanoma
      Blood Cancer
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Immune Checkpoint Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Immune Checkpoint Inhibitors market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Immune Checkpoint Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Immune Checkpoint Inhibitors submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Immune Checkpoint Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Immune Checkpoint Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now